Optimum Investment Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-160
| Closed | -$6.14K | – | 619 |
|
|
2025
Q2 | $6.14K | Sell |
160
-285
| -64% | -$10.9K | ﹤0.01% | 536 |
|
|
2025
Q1 | $17.2K | Hold |
445
| – | – | 0.01% | 456 |
|
|
2024
Q4 | $15.1K | Hold |
445
| – | – | 0.01% | 463 |
|
|
2024
Q3 | $18.2K | Sell |
445
-560
| -56% | -$22.9K | 0.01% | 459 |
|
|
2024
Q2 | $38.7K | Hold |
1,005
| – | – | 0.02% | 379 |
|
|
2024
Q1 | $43.1K | Buy |
1,005
+160
| +19% | +$6.6K | 0.02% | 382 |
|
|
2023
Q4 | $31.3K | Sell |
845
-640
| -43% | -$23K | 0.02% | 395 |
|
|
2023
Q3 | $53.8K | Hold |
1,485
| – | – | 0.03% | 352 |
|
|
2023
Q2 | $52.9K | Hold |
1,485
| – | – | 0.03% | 368 |
|
|
2023
Q1 | $52.8K | Sell |
1,485
-1,200
| -45% | -$42K | 0.03% | 362 |
|
|
2022
Q4 | $94.4K | Hold |
2,685
| – | – | 0.05% | 275 |
|
|
2022
Q3 | $79K | Sell |
2,685
-115
| -4% | -$4.36K | 0.04% | 311 |
|
|
2022
Q2 | $152K | Hold |
2,800
| – | – | 0.08% | 225 |
|
|
2022
Q1 | $152K | Hold |
2,800
| – | – | 0.06% | 253 |
|
|
2021
Q4 | $154K | Hold |
2,800
| – | – | 0.06% | 271 |
|
|
2021
Q3 | $134K | Sell |
2,800
-4,220
| -60% | -$212K | 0.06% | 292 |
|
|
2021
Q2 | $349K | Sell |
7,020
-800
| -10% | -$38.4K | 0.11% | 184 |
|
|
2021
Q1 | $349K | Sell |
7,820
-2,240
| -22% | -$102K | 0.1% | 193 |
|
|
2020
Q4 | $463K | Sell |
10,060
-2,400
| -19% | -$110K | 0.14% | 140 |
|
|
2020
Q3 | $586K | Sell |
12,460
-560
| -4% | -$28.1K | 0.2% | 113 |
|
|
2020
Q2 | $664K | Sell |
13,020
-1,520
| -10% | -$78K | 0.23% | 96 |
|
|
2020
Q1 | $689K | Buy |
14,540
+960
| +7% | +$51.2K | 0.28% | 77 |
|
|
2019
Q4 | $798K | Buy |
13,580
+9,470
| +230% | +$527K | 0.24% | 107 |
|
|
2019
Q3 | $219K | Buy |
4,110
+1,904
| +86% | +$97.9K | 0.07% | 250 |
|
|
2019
Q2 | $110K | Buy |
2,206
+3
| +0.1% | +$151 | 0.04% | 361 |
|
|
2019
Q1 | $115K | Buy |
2,203
+2
| +0.1% | +$100 | 0.04% | 355 |
|
|
2018
Q4 | $105K | Buy |
2,201
+2
| +0.1% | +$98 | 0.04% | 357 |
|
|
2018
Q3 | $110K | Buy |
2,199
+1,033
| +89% | +$52.5K | 0.03% | 384 |
|
|
2018
Q2 | $59K | Buy |
1,166
+2
| +0.2% | +$101 | 0.02% | 500 |
|
|
2018
Q1 | $57K | Buy |
+1,164
| New | +$54.2K | 0.02% | 509 |
|
|
2015
Q1 | $13K | Buy |
218
+89
| +69% | +$5.1K | ﹤0.01% | 769 |
|
|
2014
Q4 | $7K | Buy |
129
+2
| +2% | +$112 | ﹤0.01% | 881 |
|
|
2014
Q3 | $7K | Buy |
127
+1
| +0.8% | +$61 | ﹤0.01% | 798 |
|
|
2014
Q2 | $8K | Buy |
126
+2
| +2% | +$135 | ﹤0.01% | 799 |
|
|
2014
Q1 | $8K | Buy |
124
+2
| +2% | +$135 | ﹤0.01% | 626 |
|
|
2013
Q4 | $8K | Buy |
122
+1
| +0.8% | +$65 | ﹤0.01% | 627 |
|
|
2013
Q3 | $8K | Buy |
+121
| New | +$7.79K | ﹤0.01% | 600 |
|
Other funds holding GSK
JEST
Optimum Investment Advisors's GSK Position: Q3 2025 in Review
Optimum Investment Advisors sold out of GSK (GSK) in Q3 2025, closing a stake of 160 shares — an estimated $6.14K sold.
Optimum Investment Advisors first reported a position in GSK in Q3 2013 and held it in 37 quarters. The position peaked at $798K in Q4 2019. 896 funds tracked by Wall St. Rank hold GSK as of Q3 2025.
- Optimum Investment Advisors reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
- Optimum Investment Advisors sold 160 GSK shares in Q3 2025, an estimated $6.14K.
- Optimum Investment Advisors first reported a position in GSK in Q3 2013 and held it in 37 quarters.
- Optimum Investment Advisors's GSK position peaked at $798K in Q4 2019.
- 896 funds tracked by Wall St. Rank held GSK as of Q3 2025.
Based on Optimum Investment Advisors's 13F filing for Q3 2025, filed 21 Oct 2025.